Pregnant Women With Malignant Ovarian Tumors: A Case Series

Q3 Medicine
H. Azimi, Seyyed Rasoul Sajjadi, S. Saeed, M. Nakhaee, A. Jafarian, B. Davachi, Arezoo Naderi Moghaddam, Toktam Dehghani, Z. Yousefi
{"title":"Pregnant Women With Malignant Ovarian Tumors: A Case Series","authors":"H. Azimi, Seyyed Rasoul Sajjadi, S. Saeed, M. Nakhaee, A. Jafarian, B. Davachi, Arezoo Naderi Moghaddam, Toktam Dehghani, Z. Yousefi","doi":"10.18502/acta.v61i3.12741","DOIUrl":null,"url":null,"abstract":"Ovarian cancer management during pregnancy is a topic of limited research due to low occurrence rates of malignant adnexal tumors. To shed further light on this issue, we present a case series of 22 pregnant ovarian cancer patients referred to an academic hospital's gynecology oncology department over six years. Data on each patient's demographic and clinical background were collected using a registry software recording surgical tumor staging, disease-free survival (DFS), and overall survival (OS). According to the data analysis reports, subtype epithelial tumor and germ cell pathology were equally 45.4%. However, sex-cord tumors were observed in a smaller percentage of cases (9.1%). Serous adenocarcinoma was the most common subtype among those with epithelial tumors (60%). Meanwhile, 72.7% of these pregnant women had a palpable mass in physical examination. In addition, adnexal mass was detected in 95.4% of ultrasonography. Due to the young age of the patients, fertility-preserving surgery was performed on 63.6% of patients, and chemotherapy was prescripted on 59% of patients. Over a six-year follow-up period, there was a recurrence rate of 22.7%, while DFS and OS were reported as 56% and 82%, respectively. In conclusion, treatment of ovarian malignancies during pregnancy requires an experienced multidisciplinary approach. However, more extensive studies with larger samples are needed to gain more insight into the treatment of ovarian cancer during pregnancy.  ","PeriodicalId":6946,"journal":{"name":"Acta medica Iranica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Iranica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/acta.v61i3.12741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Ovarian cancer management during pregnancy is a topic of limited research due to low occurrence rates of malignant adnexal tumors. To shed further light on this issue, we present a case series of 22 pregnant ovarian cancer patients referred to an academic hospital's gynecology oncology department over six years. Data on each patient's demographic and clinical background were collected using a registry software recording surgical tumor staging, disease-free survival (DFS), and overall survival (OS). According to the data analysis reports, subtype epithelial tumor and germ cell pathology were equally 45.4%. However, sex-cord tumors were observed in a smaller percentage of cases (9.1%). Serous adenocarcinoma was the most common subtype among those with epithelial tumors (60%). Meanwhile, 72.7% of these pregnant women had a palpable mass in physical examination. In addition, adnexal mass was detected in 95.4% of ultrasonography. Due to the young age of the patients, fertility-preserving surgery was performed on 63.6% of patients, and chemotherapy was prescripted on 59% of patients. Over a six-year follow-up period, there was a recurrence rate of 22.7%, while DFS and OS were reported as 56% and 82%, respectively. In conclusion, treatment of ovarian malignancies during pregnancy requires an experienced multidisciplinary approach. However, more extensive studies with larger samples are needed to gain more insight into the treatment of ovarian cancer during pregnancy.  
妊娠妇女恶性卵巢肿瘤:一个病例系列
由于恶性附件肿瘤的发生率低,妊娠期卵巢癌的治疗是一个研究有限的课题。为了进一步阐明这一问题,我们提出了一个病例系列22怀孕卵巢癌患者转介到一个学术医院的妇科肿瘤科超过六年。使用注册软件收集每位患者的人口统计学和临床背景数据,记录手术肿瘤分期、无病生存期(DFS)和总生存期(OS)。根据数据分析报告,亚型上皮肿瘤和生殖细胞病理均为45.4%。然而,性索肿瘤在较小比例的病例中被观察到(9.1%)。浆液性腺癌是上皮性肿瘤中最常见的亚型(60%)。72.7%的孕妇在体格检查中有可触及的肿块。此外,95.4%的超声检查可检出附件肿块。由于患者年龄偏小,63.6%的患者行保生育手术,59%的患者行化疗。在六年的随访期间,复发率为22.7%,而DFS和OS分别为56%和82%。总之,治疗卵巢恶性肿瘤在怀孕期间需要一个经验丰富的多学科的方法。然而,为了更深入地了解怀孕期间卵巢癌的治疗方法,需要更广泛的研究,样本量更大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta medica Iranica
Acta medica Iranica Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
83
审稿时长
18 weeks
期刊介绍: ACTA MEDICA IRANICA (p. ISSN 0044-6025; e. ISSN: 1735-9694) is the official journal of the Faculty of Medicine, Tehran University of Medical Sciences. The journal is the oldest scientific medical journal of the country, which has been published from 1960 onward in English language. Although it had been published quarterly in the past, the journal has been published bimonthly (6 issues per year) from the year 2004. Acta Medica Iranica it is an international journal with multidisciplinary scope which publishes original research papers, review articles, case reports, and letters to the editor from all over the world. The journal has a wide scope and allows scientists, clinicians, and academic members to publish their original works in this field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信